Multicancer Detection: Is It Ready for Prime Time? Hear the regulatory perspective from FDA Oncology's Dr. Jamie Brewer Jamie Brewer tomorrow, May 31, #ASCO24, 2:45-3:45 pm CT, Hall A. Spoiler: there are hurdles to overcome. meetings.asco.org/2024-asco-annu… #OCETalks

If you are attending #ASCO24, you won’t want to miss the @NIHDirector and Dr. Kimryn Rathmell's discussion on "How and Where Will Public Investment Accelerate Progress in Oncology?" at the ASCO annual meeting on June 1! spr.ly/6012eik3a #CancerResearch #Oncology

Join FDA Oncology June 3, 11:30 am CT for #ASCO24 FDA Special Session: Improving Global Access to Cancer Therapies Through Regulatory Authority Collaboration. Angelo de Claro, presentation and panelist; Richard Pazdur, moderator. meetings.asco.org/2024-asco-annu… #OCETalks

Project 5 in 5 crowdsourcing results will be shared with government agencies, clinical trial cooperative groups and others interested in implementing these pragmatic clinical trials. 💡 Submit pragmatic trial ideas here: shareyourvoice.ideascalegov.com/c/ #OCEProject5in5

Tomorrow, July 11! Join us for a Cancer Cabinet Community Conversation to hear FDA Oncology division directors discuss major advances in cancer treatment since 2017, as well as an overview of OCE projects. ⤵️ surveymonkey.com/r/MLH7VJZ #BidenCancerMoonshot

Thank you to FDA Oncology Center of Excellence experts for the July 11 #ConversationsOnCancer discussion OCE's role in cancer drug development, regulation, and patient advocacy since our inception in 2017 as part of the #BidenCancerMoonshot! ICYMI: youtube.com/live/WaVuJalIn…

This is America. No coronations. We need an open convention. My personal opinion.

FDA grants accelerated approval to afamitresgene autoleucel for unresectable or metastatic synovial sarcoma. fda.gov/drugs/resource… #OCENewsBurst

FDA approves neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer fda.gov/drugs/resource… #OCENewsBurst

Terrible humanitarian crisis with significant public health, implications for the region and beyond nytimes.com/2024/08/26/wor… via The New York Times

I don’t use a wheelchair, but my legs are too weak to use stairs so I have to crawl too. Most Underground stations in London are not accessible! Disgrace' that Baroness Tanni Grey-Thompson had to 'crawl off' train - ParalympicsGB chief - The Athletic apple.news/AQgG0Xh6MSVaio…

The Duffy Null Phenotype — Addressing a Source of Discrimination in Cancer Care | New England Journal of Medicine nejm.org/doi/full/10.10… This important information needs to be incorporated into standards for cancer clinical trial eligibility!

nytimes.com/2024/12/13/hea… via The New York Times As someone paralyzed 6 months before the Salk vaccine became available I find the push to end polio vaccination abominable.

When Diversity Goals Meet Multiregional Trials | New England Journal of Medicine nejm.org/doi/full/10.10… Very nice article by Gautam Mehta, MD et al about diversity in multiregional trials. Having more trial sites in underserved regions like Africa is a great idea.

Drug Development Is Slowing Down After Cuts at the FDA - The Wall Street Journal. Missing Deadlines? This is not business as usual. Timelines are mandated by law. apple.news/A9OJMtm78Rb2Zo…

cancerletter.com/regulatory-new… In ordinary times, this would not pass muster

FDA to limit COVID shot approval to older adults, those with medical conditions - The Washington Post -Amazed NEJM published this without editorial comment apple.news/AdQ6Ri5QOQ3uum…

Robinson’s No.1 Ribs on the West plaza of the East building at McCormick Place the best part of #asco25 yet!

Top F.D.A. Official Overrode Scientists on Covid Shots nytimes.com/2025/07/02/hea… via The New York Times No one who knows the situation is it all surprised

Laura Loomer purges CBER Chief- right result wrong reason!